ADC Therapeutics SA
1.22USD
-0.0800 (-6.15%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.21▲ | $-0.22 | 1 | 0 |
| Next quarter | $-0.2▲ | $-0.21 | 1 | 1 |
| Current year | $-0.76▲ | $-0.85 | 4 | 0 |
| Next year | $-0.68▼ | $-0.62 | 0 | 2 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.22 | $-0.11 | +0.11 (+49.1%) |
| 2026-03-31 | $-0.2 | $-0.21 | -0.01 (-4.1%) |
| 2025-12-31 | $-0.27 | $-0.04 | +0.23 (+85.1%) |
| 2025-09-30 | $-0.36 | $-0.3 | +0.06 (+17.4%) |
76 ratings from 12 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Guggenheim | Maintained | Buy | $10 $5 | Aug 17, 2026 |
| HC Wainwright & Co. | Downgraded from Buy | Neutral | — | Jun 8, 2026 |
| RBC Capital | Downgraded from Outperform | Sector Perform | $6 $2 | Jun 4, 2026 |
| RBC Capital | Reiterated | Outperform | $6 | May 5, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $8 | May 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $7 $8 | Mar 23, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $8 $7 | Oct 16, 2025 |
| Guggenheim | Reiterated | Buy | $10 | Aug 13, 2025 |
| RBC Capital | Maintained | Outperform | $8 $5 | Jun 20, 2025 |
| Guggenheim | Maintained | Buy | $7 $10 | Jun 13, 2025 |
| RBC Capital | Reiterated | Outperform | $8 | May 15, 2025 |
| Guggenheim | Maintained | Buy | $10 $7 | Mar 31, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $8 | Mar 31, 2025 |
| Cantor Fitzgerald | Reiterated | Overweight | — | Mar 7, 2025 |
| Stephens & Co. | Maintained | Overweight | $6 $8 | Feb 24, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $8 | Jan 6, 2025 |
| Guggenheim | Reiterated | Buy | $10 | Dec 12, 2024 |
| HC Wainwright & Co. | Reiterated | Buy | — | Dec 11, 2024 |
| Stephens & Co. | Initiated | Overweight | $6 | Nov 8, 2024 |
| HC Wainwright & Co. | Reiterated | Buy | $8 | Aug 8, 2024 |
| RBC Capital | Reiterated | Outperform | $8 | Aug 7, 2024 |
| Cantor Fitzgerald | Initiated | Overweight | — | May 30, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $9 $8 | May 7, 2024 |
| HC Wainwright & Co. | Reiterated | Buy | $9 | Apr 15, 2024 |
| Guggenheim | Reiterated | Buy | — | Apr 5, 2024 |
31 filings from 13 insiders · 11 buy / 1 sell over 6m
Officers and directors of ADCT, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ZAKI MOHAMEDOfficer | Grant | 213.9k | — | — | Jun 30, 2026 |
| MALLIK AMEETChief Executive Officer | Grant | 675.0k | — | — | Jun 30, 2026 |
| CARMONA JOSEChief Financial Officer | Grant | 203.7k | — | — | Jun 30, 2026 |
| GRAHAM PETER JOfficer | Grant | 221.1k | — | — | Jun 30, 2026 |
| HUG PETERDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| MONGES VIVIANEDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| AZELBY ROBERT WDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| SANDOR VICTORDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| BIZZARI JEAN-PIERREDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| SQUARER RON RDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| COUGHLIN TIMOTHY PDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| REDMILE GROUP, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sellindirect | 5.88M | $3.28 | $19.64M | Apr 2, 2026 |
| KALLEBO LISA MICHELLEOfficer | Grant | 62.9k | $3.99 | $251k | Feb 13, 2026 |
| ZAKI MOHAMEDOfficer | Grant | 285.2k | $3.99 | $1.14M | Feb 13, 2026 |
| MALLIK AMEETChief Executive Officer | Grant | 900.0k | $3.99 | $3.59M | Feb 13, 2026 |
| CARMONA JOSEChief Financial Officer | Grant | 271.6k | $3.99 | $1.08M | Feb 13, 2026 |
| GRAHAM PETER JOfficer | Grant | 294.8k | $3.99 | $1.18M | Feb 13, 2026 |
| HUG PETERDirector | Grant | 40.0k | — | — | Jun 3, 2025 |
| MONGES VIVIANEDirector | Grant | 40.0k | — | — | Jun 3, 2025 |
| AZELBY ROBERT WDirector | Grant | 40.0k | — | — | Jun 3, 2025 |
Analyst Ratings
3 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 3 | 2 | 0 | 0 | Buy2.40 |
| 1 mo ago | 0 | 3 | 2 | 0 | 0 | Buy2.40 |
| 2 mo ago | 0 | 3 | 2 | 0 | 0 | Buy2.40 |